NCT03600779Recruiting
Application of ihMT MRI in Multiple Sclerosis
Application of the Inhomogeneous Magnetisation Transfer MRI (ihMT) Technique, a New Myelin-specific MRI Technique, in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- First submitted
- 6 Jul 2018
- Start date
- 14 Jun 2018
- Primary completion date
- 14 Aug 2027
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Diseases
- Multiple sclerosis
- NCT number
- NCT03600779
What you commit to
- Study type: Interventional
- Planned participants: 85
- From 14 Jun 2018 to the primary completion date, 14 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- For Patients and Controls :
- Patients with the usual contraindications for MRI (pacemaker, agitation, metal shards, claustrophobia)
- Patients at risk of non-compliance to the exam: basic problems with understanding, confusion, involuntary movements, poor tolerance of prolonged supine position
- Patients who are unable to give their consent: problems with understanding, lack of vigilance, confusion
- Woman who is pregnant and breastfeeding
- Patients with a history of neurological or psychiatric condition
- Patients under guardianship or trusteeship
Other
- For patients only :
- Patients with a progressive form of MS other than the early relapsing-remitting form (primary progressive or secondary progressive)
Who the study is looking for
- For Patients and Controls :
- Adult patient, male and female, age 18 to 45
- Patient affiliated with health insurance coverage,
- Patient who signed a free and informed consent after receiving detailed, understandable and honest information,
- For patients only :
- Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria or progressive
- Patients treated or not treated with first-line disease modifying therapy
- Detection of at least one post-Gadolinium injection active lesion identified on the initial brain MRI (T0) or a chronic active lesion (PRL: Paramagnetic rim lesions)
Age in the registry: 18 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assistance Publique Des Hotipaux de Marseille Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.